Awards & Recognitions
A summary of the awards and achievements made by EAVE II and it's team members.
2021
Health Data Research UK's Annual Awards: Impact of the Year
On the 23 June 2021, the EAVE II team were awarded the HDR UK Impact of the year Award at the annual HDR Scientific Conference. This award was open to all works which contribute to HDR UK's goal to unite the UK's health data and to enable discoveries that improve people's lives.
EAVE II's submission was titled "Real-world validation of COVID-19 vaccine effectiveness through rapid use of linked, national data", which was based off of the team's milestone study that found COVID-19 vaccines were effective at reducing COVID-19 related hospital admissions.
Read more about EAVE II's submitted work
Find out more about the 2021 HDR UK Awards
The University of Edinburgh's Chancellor's Award for Research Excellence
On the 20 December 2021, EAVE II's Principal Investigator Professor Sir Aziz Sheikh was awarded the University of Edinburgh's Chancellor Award for Research Excellence in recognition of "the way in which he has enhanced the University’s reputation through both his research, his inspiration and support of others’ research, alongside his recent tireless commitment to generating, analysing and utilising for policy purposes, the very best linked data for understanding Covid-19."
Read more about Aziz's Chancellor's Award
Find out more about the Chancellor's Awards
Find out more about the 2021 Chancellor's Award winners
2022
Research Honours Aotearoa Awards: The Liley Medal
On the 23 November 2022, EAVE II team member Professor Colin Simpson was awarded the Liley Medal for his contributions to the project's milestone work investigating the real-world effectiveness of the early COVID-19 vaccines.
The medal was presented to Professor Simpson by New Zealand's Royal Society Te Apārangi and Health Research Council as part of the 2022 Research Honour Aotearoa Awards.
Find out more about the 2022 Research Honours Aotearoa Awards
Find out more about the Liley Medal
2023
Royal Society of Edinburgh Mary Sommerville Medal
On the 31 March 2023, the Royal Society of Edinburgh (RSE) announced that the EAVE II team were the first-time recipients of their prestigious Mary Sommerville Medal, which recognises exceptional achievements in research teamwork and collaborations.
Read the full Usher Institute news item
Read more in the RSE ReSourcE magazine
Find out more about the 2023 RSE Medal winners
Find out more about the RSE Mary Sommerville Medal
Royal Statistical Society's Florence Nightingale Award
On the 6 July 2023, EAVE II's Long COVID team were presented with the Royal Statistical Society's Florence Nightingale Award for Excellence in Healthcare Data Analytics.
What is the Florence Nightingale Award?
2024
2024 Health Data Research UK Annual Awards and Recognitions: Reproducibility
At the Annual HDR UK Conference on 5 March 2024, it was announced that EAVE II was one of five research teams to receive the HDR UK Recognition for Reproducibility.
Find out more about the 2024 HDR UK Annual Awards and Recognitions
Every month, the Health Data Research UK's Impact Committee selects an impactful paper from across HDR UK and their contributors as the Open Access Publication of the Month.
Find out more about the HDR UK Impact Committee
June 2021
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
EAVE II's milestone study, which pointed to the success of first dose mass vaccination in reducing COVID-19 hospitalisations across Scotland.
Read our full summary in plain English
November 2021
COVID-19 hospital admissions and deaths post BNT162b2 and ChAdOx1 vaccinations: National prospective cohort study of 2.57 million people in Scotland
An EAVE II research paper which looked at the number of people in Scotland who have died from or been admitted to hospital with COVID-19 after at least one vaccine dose.
Read our full summary in plain English
Read the HDR UK article
January 2022
External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland
June 2021
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
EAVE II's study of 2.53 million first COVID-19 vaccine doses across Scotland which showed that there were small increases in risk for some adverse events following the Oxford-AstraZeneca vaccine.
Read our full summary in plain English
July 2021
Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales
An EAVE II study which found that 36% fewer people were admitted to hospital in Scotland and Wales in the first lockdown due to asthma.
Read our full summary in plain English
September 2021
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
EAVE II's study of 2.53 million first COVID-19 vaccine doses across Scotland which showed that there were small increases in risk for some adverse events following the Oxford-AstraZeneca vaccine.
Read our full summary in plain English
Read the HDR UK article
December 2021
COVID-19 hospital admissions and deaths post BNT162b2 and ChAdOx1 vaccinations: National prospective cohort study of 2.57 million people in Scotland
An EAVE II research paper which looked at the number of people in Scotland who have died from or been admitted to hospital with COVID-19 after at least one vaccine dose.
Read our full summary in plain English
Read the HDR UK article
April 2022
COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales
A study from the EAVE II connected project DaC-VaP, looking at the uptake, effectiveness, and waning of COVID-19 vaccines in 82,959 health care workers.
Read our full summary in plain English
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
EAVE II study which showed that protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses. This case study was written about the paper's pre-print article before the peer reviewed paper was published.
Read our full summary in plain English
December 2022
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil
EAVE II study which showed that protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses.
Read our plain English summary
COVID-19 hospitalisations among school-age children with underlying health conditions
Study looking at the risk of COVID-19 hospitalizations among school-aged children.
February 2023
Four-nations study showed vaccine protection against severe COVID-19 outcomes wanes over time
Study from the DaC-VaP-2 project that analysed data from 12.9 million individuals across the UK to explore the effectiveness of COVID-19 vaccines.
2022
EAVE II Principal Investigator Professor Sir Aziz Sheikh was awarded a Knighthood in the late Her Majesty the Queen's 2022 Birthday Honours list for services to COVID-19 Research and Policy.
2022
Health Data Research UK's Annual Awards: Team of the Year 2022
The EAVE II team were shortlisted for the HDR UK Team of the Year award 2022.